REFERENCES
- Boyce JM. Increasing prevalence of methicillin-resistant Staphylococcus aureus in the United States. Infect Control Hosp Epidemiol 1990; 11: 639–642.
- Waldvogel FA. Osteomyelitis. In: Gorbach SL, Bartlett JG, Blackow NR (ed): Infectious diseases. Philadelphia: Saunders, 1992: 1125-1129.
- Greenberg RN. Treatment of bones and vascular-access-associated gram-positive bacteria infections with teicoplanin. Antimicrob Agents Chemother 1990; 34: 2392–2397.
- Wilson APR, Taylor B, Treasure T, et al. Antibiotic pro-phylaxis in cardiac surgery: serum and tissue levels of teicoplanin, flucloxacin and tobramycin. J Antimicrob Chemother 1988; 21: 201–202.
- National Committee for Clinical and Laboratory Standards; Performance standards for antimicrobial disk sus-ceptibility test. NCCLS, Villanova, PA,1984.
- Wagner DK. Treatment of bone and joint infections with teicoplanin: a retrospective analysis of 50 cases. Int J Antimicrob Agents 1996; 7: 49–51.
- Winkler G, Weinberg MD. Safety and efficacy of teicoplanin for bone and joint infections. South Med J 1993; 86: 891–97.
- Graninger W, Wenisch C, Menschik M, Karimi J, Presterl E. Experience with outpatient intravenous teicoplanin therapy for chronic osteomyelitis. Eur J Clin Microbiol Infect Dis 1995; 14: 634–647.
- Greenberg RN. Treatment of bone, joint and vascular-access-associated Gram positive bacterial infections with teicoplanin. Antimicrob Agents Chemother 1990; 34: 2392–97.